To evaluate the feasibility of targeted renal therapy (TRT) to decrease the rate of contrast-induced nephropathy (CIN) during endovascular aortic aneurysm repair (EVAR) in patients at risk for CIN.
Methods:
A prospective nonrandomized analysis of TRT was performed in 10 high-risk patients (8 men; median age 66.5 years, range 56–80) with pre-existing renal insufficiency. TRT involved high-dose intrarenal artery infusions of fenoldopam (FEN), a short acting selective dopamine-1 agonist and renal arteriolar vasodilator, delivered percutaneously via a left brachial access using the 5-F Benephit PV Infusion System during EVAR.
Results:
There were no device-related complications. TRT infusion duration ranged from 3.5 to 6.0 hours (median 4.5). Median contrast dosage was 120 mL (range 50–200). At 24 and 72 hours after EVAR, creatinine clearance (CrCl) had improved in 7 (70%) patients, remained unchanged in 2 (20%), and declined >25% in 1 (10%); the latter returned to baseline on day 5. At 30 days, 7 (70%) patients had improved CrCl and 3 (30%) remained unchanged.
Conclusion:
TRT is feasible during EVAR in high-risk patients. Further investigation is warranted to determine the safety and efficacy of TRT in preserving renal function during EVAR.
ParodiJCPalmazJCBaroneHD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Ann Vasc Surg.1991; 5: 491–499.
2.
WrightRSReederGSHerzogCA. Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med.2002; 137: 563–570.
3.
McAlisterFAEzekowitzJTonelliM. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004; 109: 1004–1009.
4.
HerzogCAMaJZCollinsAJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med.1998; 339: 799–805.
5.
GottliebSSAbrahamWButlerJ. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail.2002; 8: 136–141.
6.
CooperWAO?BrienSMThouraniVH. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: Results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation. 2006; 113: 1063–1070.
7.
HillisGSCroalBLBuchanKG. Renal function and outcome from coronary artery bypass grafting: Impact on mortality after a 2.3-year follow-up. Circulation. 2006; 113: 1056–1062.
8.
AzizzadehASanchezLAMillerCC. Glomerular filtration rate is a predictor of mortality after endovascular abdominal aortic aneurysm repair. J Vasc Surg.2006; 43: 14–18.
9.
PowellRJRoddySPMeierGH. Effect of renal insufficiency on outcome following infrarenal aortic surgery. Am J Surg.1997; 174: 126–130.
10.
MatsumuraJSBrewsterDCMakarounMS. A multicenter controlled clinical trial of open versus endovascular treatment of abdominal aortic aneurysm. J Vasc Surg.2003; 37: 262–271.
11.
JohnstonKW. Multicenter prospective study of nonruptured abdominal aortic aneurysm. Part II. Variables predicting morbidity and mortality. J Vasc Surg.1989; 9: 437–447.
12.
MillerDMeyersB. Pathophysiology and prevention of renal failure associated with thoracoabdominal or abdominal aortic surgery. J Vasc Surg.1987; 5: 518–23.
13.
GreenbergRKChuterTASternberghWC. Zenith AAA endovascular graft: Intermediate-term results of the US multicenter trial. J Vasc Surg.2004; 39: 1209–1218.
14.
GreenbergRKChuterTALawrence-BrownM. Analysis of renal function after aneurysm repair with a device using suprarenal fixation (Zenith AAA Endovascular Graft) in contrast to open surgical repair. J Vasc Surg.2004; 39: 1219–1228.
15.
ForbesTLHardingGELawlorDK. Comparison of renal function after endovascular aneurysm repair with different transrenally fixated endografts. J Vasc Surg.2006; 44: 938–942.
16.
CarpenterJPFairmanRMBarkerCF. Endovascular AAA repair in patients with renal insufficiency: Strategies for reducing adverse renal events. Cardiovasc Surg.2001; 9: 559–564.
17.
StoneGWMcCulloughPATumlinJA. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA. 2003; 290: 2284–2291.
18.
McCulloughPAWolynRRocherLL. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med.1997; 103: 368–375.
19.
HeymanSNClarkBAKaiserN. Radio-contrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol.1992; 3: 58–65.
20.
ArakawaKSuzukiHNaitohM. Role of adenosine in the renal responses to contrast medium. Kidney Int.1996; 49: 1199–1206.
21.
TeirsteinPSPriceMJMathurVS. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. Am J Cardiol.2006; 97: 1076–1081.
BushRLJohnsonMLHedayatiN. Performance of endovascular aortic aneurysm repair in high-risk patients: Results from the Veterans Affairs National Surgical Quality Improvement Program. J Vasc Surg.2007; 45: 227–235.
24.
EVAR trial participants. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): Randomised controlled trial. Lancet. 2005; 365: 2187–2192.
BarrettBJParfreyPS. Preventing neuropathy induced by contrast medium. N Eng J Med.2006; 354: 379–386.
27.
MooreNNLapsleyMNordenAG. Does N-acetylcysteine prevent contrast-induced nephropathy during endovascular AAA repair? A randomized controlled pilot study. J Endovasc Ther.2006; 13: 660–666.
28.
AllieDEHebertCJWalkerCM. Multifactorial acute renal failure treated with percutaneous targeted renal therapy (TRT): A case of “dialysis rescue.”J Invasive Cardiol.2007; 19: E27–E30.
29.
AllieDE. Clinical use of targeted renal therapy in the “real world”: Abdominal aortic aneurysm, coronary artery bypass graft, percutaneous transluminal angioplasty and beyond!Vasc Dis Manage. 2006; 3(Suppl): 9–11.
30.
RanucciMSoroGBarzaghiN. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg.2004; 78: 1332–1338.
31.
HuyngTTvan EpsRGAzizzadehA. Glomerular filtration rate is superior to serum creatinine for predication of mortality following thoracoabdominal aortic surgery. J Vasc Surg.2005; 42: 206–212.
